TY - JOUR
T1 - Dihydroergotamine as a pharmacologic euglycemic clamp in the surgically traumatized rabbit
AU - Mossberg, Kurt A.
AU - Taegtmeyer, Heinrich
N1 - Funding Information:
From the Division of Cardiology Department of Medicine, University of Texas Medical School, Houston, TX. Suppotted in part by the Diabetes Research and Education Foundation, American Diabetes Association-Texas Afiliate, and by a Grant-in-Aid from the American Heart Association-Texas Affiliate. Address reprint requests to Kurt A. Mossberg PhD. Division of Cardiology. MSB 1.246, 6431 Fannin, Houston, TX 77030. Copyright 0 1991 by W.B. Saunders Company 0026049519114006-0007$03.OOlO
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1991/6
Y1 - 1991/6
N2 - We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.
AB - We assessed the utility of a pharmacologic euglycemic clamp technique by examining the metabolic and hemodynamic changes brought about by administration of dihydroergotamine (DHE) prior to anesthesia and operative trauma in the rabbit. New Zealand white rabbits received an intramuscular injection of 0.15 mg DHE/kg body weight 20 minutes before general anesthesia and minor surgical trauma, which consisted of carotid artery and jugular vein catheterizations followed by femoral artery and vein cannulations. Arterial blood was sampled every 20 minutes and assayed for glucose, lactate, nonesterified fatty acids (NEFA), and insulin. Rates of hindlimb skeletal muscle glucose uptake (Rg) and blood flow were determined 2 hours after the initial administration of DHE. DHE did not produce any effects on heart rate, blood pressure, blood flow, and Rg when compared with control animals. Liver glycogen levels were significantly higher after DHE treatment (140 ± 31.4 v 34 ± 9.6 μmol/g dry weight, P<.01). Those animals receiving DHE had significantly lower and more stable plasma glucose levels than untreated animals (ranges, 5 to 9 v 7 to 22 μmol/mL plasma) and circulating NEFA were also lower and less variable (ranges, 0.1 to 1.0 v 0.1 to 2.0 μEq/mL plasma). The results show that DHE prevents stress-induced hyperglycemia in vivo in the rabbit without altering glucose uptake by skeletal muscle. The technique provides control over circulating glucose levels during the study of skeletal muscle glucose uptake without apparent negative physiologic effects.
UR - http://www.scopus.com/inward/record.url?scp=0025800988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025800988&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(91)90049-3
DO - 10.1016/0026-0495(91)90049-3
M3 - Article
C2 - 1865822
AN - SCOPUS:0025800988
SN - 0026-0495
VL - 40
SP - 594
EP - 599
JO - Metabolism
JF - Metabolism
IS - 6
ER -